Who Owns Propecia?

• Parent Company: Merck & Co.
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: NYSE: MRK

• Founded: 1997
• Founders: Merck & Co. (internal development)

• Founded: 1668
• Headquarters: Rahway, New Jersey, USA
• Company Type: Publicly Traded
• Stock: NYSE: MRK
• Revenue: approximately $63.6 billion (FY2024)
• Employees: Approximately 72,000

Visit Merck & Co. website

• Headquarters: Rahway, New Jersey, USA
• Manufacturing / Operations: United States, Belgium, Germany, Ireland

Merck has established comprehensive sustainability and ethics frameworks that apply across its pharmaceutical operations, including the manufacturing and distribution of Propecia. The company has committed to achieving net-zero greenhouse gas emissions across its global operations by 2045, aligning with Science Based Targets initiative guidelines.

Environmental Stewardship: Merck has implemented green chemistry principles in drug manufacturing, including developing more sustainable synthesis processes. In 2024, Merck received the EPA Green Chemistry Challenge Award for developing a continuous manufacturing process for Keytruda, demonstrating the company's commitment to sustainable pharmaceutical production that extends to its entire product portfolio.

Ethical Clinical Research: Merck maintains strict ethical standards in clinical trials and drug development. The company conducts extensive clinical research with proper informed consent and safety monitoring. Propecia underwent rigorous clinical trials involving thousands of participants before FDA approval, establishing its efficacy and safety profile.

Access and Affordability: Merck has implemented programs to improve access to medications in developing countries. While Propecia is primarily marketed in developed economies, Merck's global access initiatives support broader healthcare access through tiered pricing and partnership programs.

Supply Chain Responsibility: Merck maintains comprehensive supplier responsibility programs, ensuring ethical sourcing of raw materials and responsible manufacturing practices throughout its supply chain. The company requires suppliers to adhere to strict quality and ethical standards.

Merck has received numerous awards and recognition for its pharmaceutical innovation, research excellence, and corporate responsibility, though specific awards for Propecia itself are limited as it is an individual product within Merck's broader portfolio.

Scientific Recognition: Propecia (finasteride) has been recognized in the medical community for its innovation in treating male pattern baldness. The drug represents a significant advancement in dermatological treatment and has been widely cited in medical literature for its efficacy in 5-alpha reductase inhibition.

Manufacturing Excellence: In 2024, Merck received the EPA Green Chemistry Challenge Award for Greener Synthetic Pathways for developing innovative continuous manufacturing processes. While this award specifically recognized Keytruda manufacturing, it demonstrates Merck's commitment to sustainable pharmaceutical manufacturing that extends across its product lines, including products like Propecia.

Corporate Recognition: Merck has been consistently recognized as one of the world's most ethical companies by Ethisphere Institute and has received multiple sustainability awards. The company scored in the top quartile within pharmaceuticals in ESG ratings and was included in the STOXX Global ESG Leaders Index in 2024.

Medical Innovation: Merck's research and development efforts, including the development of Propecia, have contributed to the company's reputation as a leader in pharmaceutical innovation. The company's oncology and primary care divisions, which include Propecia, have been recognized for developing treatments that address significant medical needs.

Propecia has faced significant controversies and legal challenges related to its side effects, particularly concerning persistent sexual dysfunction that some users reported continuing after discontinuing the medication.

Sexual Side Effects Controversy: The most significant controversy involves reports of persistent sexual side effects including erectile dysfunction, decreased libido, and depression that some men claim continued even after stopping Propecia treatment. These reports emerged in the late 2000s and led to hundreds of lawsuits against Merck.

FDA Warning Updates: In 2011, the FDA required updates to Propecia's label to include warnings about potential sexual side effects that may continue after discontinuation of the drug. The FDA later expanded these warnings to include more specific information about potential risks.

Major Litigation: Hundreds of lawsuits were filed against Merck by men who claimed to experience lasting side effects. In 2012, these lawsuits were consolidated in New Jersey courts for centralized management. The litigation centered on whether Merck adequately warned patients and physicians about the potential for persistent side effects.

2021 Market Pull Lawsuit: In September 2021, a patient advocacy group filed a lawsuit seeking to pull Propecia and its generic versions from the market, alleging that federal regulators failed to act on evidence linking the drug to depression, erectile dysfunction, and in some cases, suicide.

Current Status: Merck has maintained that Propecia is safe and effective when used as directed, citing extensive clinical data. The company attributes reported persistent side effects to other factors and continues to market the medication with updated safety warnings. Generic versions of finasteride remain widely available following patent expiration.